<ui:composition xmlns="http://www.w3.org/1999/xhtml"
	xmlns:ui="http://java.sun.com/jsf/facelets"
	xmlns:h="http://java.sun.com/jsf/html"
	xmlns:f="http://java.sun.com/jsf/core"
	xmlns:a4j="http://richfaces.org/a4j"
	xmlns:rich="http://richfaces.org/rich">

	<h:head></h:head>
	<f:view>
		<h:body>

			<table style="margin: 0px 40px; width: 800px;">
				<tr>
					<td><font
						style="font-family: sans-serif; font-size: 16px; text-align: justify;">
						<h2 style="font-style: italic;color: #1f497d;">About Molplex</h2>
							
							<p> Molplex is  a new class of pharmaceutical company using
							highly automated decision making systems to identify  new
							treatments for infection, cancer and other serious diseases. Our
							pipeline of small-molecule therapeutics is driven by our
							proprietary platform for drug optimisation, Optiplex™. A highly
							scalable system combined with the latest in laboratory
							automation, delivering safer and more effective drugs. We
							discover novel treatments quicker and cost effectively, aiming to
							improve the health of patients around the globe. Molplex
							Pharmaceuticals is built on the following fundamentals:</p>
							<ul>
								<li>Delivering value to shareholders by licensing  a
									pipeline of small molecule pharmaceuticals for infectious
									diseases, dermatology, and oncology.</li>
								<li>Concentrating Talent &amp; Technology.  Good
									management, experienced scientists  and an integrated
									technology.</li>
								<li>Engaging new projects by applying our highly scalable
									platform to develop safer and more effective drugs.</li>
								<li>Achieving highest success rates, quickly and
									cost-effectively.</li>
							</ul><br/>
							 <strong>Organisation</strong><br/>
							<p> Founded in 2010, Molplex is a
							privately-held company, backed by a mix of private capital VC's
							and government grants. By building and advancing a valuable
							pipeline of novel compounds, Molplex continues to attract
							partners and investors worldwide.</p>
					</font></td>
				</tr>
			</table>
		</h:body>


	</f:view>

</ui:composition>